Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Docetaxel/paclitaxel

Hypersensitivity reactions: 10 case reports

    • 2 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Parisi A, et al. First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clinical and Translational Oncology 22: 158-162, No. 1, Jan 2020. Available from: URL: http://doi.org/10.1007/s12094-019-02122-x

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Docetaxel/paclitaxel. Reactions Weekly 1791, 99 (2020). https://doi.org/10.1007/s40278-020-74944-4

    Download citation